(c) GenSight Biologics

GenSight receives approval for PIONEER trial to evaluate GS030, a combination Gene Therapy & Device treatment for patients with RP. May test AMD later.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK Medicines and Healthcare Regulatory Agency (MHRA) acceptance of the Company’s Clinical Trial Application (CTA) to initiate the PIONEER Phase I/II study of GS030 in patients with Retinitis Pigmentosa (RP).